2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

www.kumc.edu

 

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium
D

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti-PD-L1 Agents and Their Combinations, and Outcomes of Pivotal Trials

By 2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium FEATURING Don Gibbons
By 2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium FEATURING Don Gibbons
0 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira
Lung
17:19
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti…

Feat. D. Gibbons
10:16
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Immunotherapy in Advanced NSCLC: Difficulties With Biomarkers Develo…

Feat. D. Gibbons
13:33
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Checkpoint Inhibitors in Stage III NSCLC (Pacific Trial Regimen) / B…

Feat. D. Gibbons
17:11
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Microbiome as a Predictive Ecosystem for Immunotherapy in NSCLC Can …

Feat. J. Zhang
12:42
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New KRAS G12C / MET Exon 14 TKI’s for Advanced NSCLC: Favorable Safe…

Feat. C. Huang
22:41
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New TKI’s in Development for Lung Cancer. An Overview of New ROS1 / …

Feat. C. Huang